Dear Dr. Walson

Clinical Therapeutics

Volumn 30, Issue 10, 2008, Pages 1932-1933

  Srinivas, Nuggehally R ^a  

^a ClinTec India International Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BOSENTAN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; ANTIHYPERTENSIVE AGENT; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; ISOENZYME; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; SLCO1B3 PROTEIN, HUMAN; SULFONAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ARTICLE; DRUG EFFECT; ENZYME INDUCTION; ENZYME SUBSTRATE; HUMAN; SINGLE DRUG DOSE; DRUG INTERACTION; LETTER; METABOLISM;

ANTIHYPERTENSIVE AGENTS; ANTITUBERCULAR AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISOENZYMES; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; RIFAMPIN; SULFONAMIDES;

EID: 55949103038     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.10.016     Document Type: Article

References (14)

1. Niemi M., Backman J.T., Fromm M.F., et al. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet 42 (2003) 819-850
2. Fromm M.F., Kauffmann H.M., Fritz P., et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157 (2000) 1575-1580
3. Kim K.A., Park P.W., Liu K.H., et al. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol 48 (2008) 66-72
4. Kyrklund C., Backman J.T., Kivisto K.T., et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (2000) 592-597
5. Backman J.T., Luurila H., Neuvonen M., and Neuvonen P.J. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78 (2005) 154-167
6. Scripture C.D., and Pieper J.A. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 40 (2001) 263-281
7. Kyrklund C., Backman J.T., Neuvonen M., and Neuvonen P.J. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 57 (2004) 181-187
8. Evers R., and Chu X.Y. Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity. Mol Pharmacol 74 (2008) 309-311
9. Sakaeda T., Fujino H., Komoto C., et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 23 (2006) 506-512
10. Zhang W., Deng S., Chen X.P., et al. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: A randomized, single-blind, placebo-controlled, crossover study. Clin Ther 30 (2008) 1283-1289
11. Treiber A., Schneiter R., Häusler S., and Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35 (2007) 1400-1407
12. Lau Y.Y., Huang Y., Frassetto L., and Benet L.Z. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81 (2007) 194-204
13. Oswald S., Giessmann T., and Luetjohann D. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 80 (2006) 477-485
14. Martin P.D., Warwick M.J., and Dane A.L. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25 (2003) 2822-2835